Ertapenem vs Piperacillin-Tazobactam for Acute Pelvic Infections
Author Information
Author(s): Subir Roy, Iliana Higareda, Edith Angel-Muller, Mahmoud Ismail, Caren Hague, Ben Adeyi, Gail L. Woods, Hedy Teppler
Primary Institution: Keck School of Medicine at USC
Hypothesis
To compare the efficacy, tolerability, and safety of ertapenem therapy with piperacillin-tazobactam therapy for the management of acute pelvic infections.
Conclusion
Ertapenem was as effective as piperacillin-tazobactam for treating acute pelvic infections and had a similar safety profile.
Supporting Evidence
- 93.9% of patients treated with ertapenem were cured compared to 91.5% with piperacillin-tazobactam.
- The median duration of therapy was 4 days for both treatment groups.
- Both treatments had similar rates of drug-related adverse events.
Takeaway
This study found that a single daily dose of ertapenem works just as well as a more frequent dose of piperacillin-tazobactam for treating infections in women's pelvic areas.
Methodology
A multicenter, double-blind, randomized study comparing ertapenem and piperacillin-tazobactam in women with acute pelvic infections.
Limitations
The study did not specify subgroup analyses for severe infections.
Participant Demographics
The majority of participants were women aged 16 and older, with a mix of ethnicities including Caucasian, Black, Hispanic, and Mestizo.
Statistical Information
Confidence Interval
95% CI for the difference, adjusting for strata, -4% to 8.8%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website